RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis.

[1]  P. Croucher,et al.  Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. , 2007, The Journal of biological chemistry.

[2]  Benjamin A Lipsky,et al.  Skin, Soft Tissue, Bone, and Joint Infections in Hospitalized Patients: Epidemiology and Microbiological, Clinical, and Economic Outcomes , 2007, Infection Control & Hospital Epidemiology.

[3]  Á. Geirsson,et al.  Víkingsson incidence due to iatrogenic infections Septic arthritis in Iceland 1990 2002 : increasing , 2008 .

[4]  P. Secchiero,et al.  Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. , 2007, Blood.

[5]  P. Kostenuik,et al.  RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. , 2007, Journal of periodontology.

[6]  C. Ohlsson,et al.  Addition of bisphosphonate to antibiotic and anti‐inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus‐induced arthritis , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[7]  G. Schett.  Cells of the synovium in rheumatoid arthritis. Osteoclasts , 2007, Arthritis research & therapy.

[8]  C. Ohlsson,et al.  Rapid systemic bone resorption during the course of Staphylococcus aureus-induced arthritis. , 2006, The Journal of infectious diseases.

[9]  J. Smith,et al.  Infectious arthritis: clinical features, laboratory findings and treatment. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  I. Holen,et al.  Role of osteoprotegerin (OPG) in cancer. , 2006, Clinical science.

[11]  P. Kostenuik.  Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. , 2005, Current opinion in pharmacology.

[12]  J. Davis,et al.  Management of bone and joint infections due to Staphylococcus aureus , 2005, Internal medicine journal.

[13]  S. Goldring,et al.  Rheumatic diseases: the effects of inflammation on bone , 2005, Immunological reviews.

[14]  A. Corrado,et al.  TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis , 2004 .

[15]  S. Mochizuki,et al.  Osteoclastogenesis Inhibitory Factor/Osteoprotegerin Reduced Bone Loss Induced by Mechanical Unloading , 2004, Calcified Tissue International.

[16]  R. Faggioni,et al.  Regulatory effects of osteoprotegerin on cellular and humoral immune responses. , 2003, Clinical immunology.

[17]  S. Hamada,et al.  Streptococcus pyogenes Infection Induces Septic Arthritis with Increased Production of the Receptor Activator of the NF-κB Ligand , 2003, Infection and Immunity.

[18]  T. Martin,et al.  Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. , 2002, The American journal of pathology.

[19]  B. Bolon,et al.  Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. , 2002, Arthritis and rheumatism.

[20]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  A. Tarkowski,et al.  Role of macrophages in Staphylococcus aureus-induced arthritis and sepsis. , 2000, Arthritis and rheumatism.

[22]  YOUHAI H. Chen,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression , 2000, The Journal of experimental medicine.

[23]  B. Wilson,et al.  Survival of Staphylococcus aureus Inside Neutrophils Contributes to Infection1 , 2000, The Journal of Immunology.

[24]  J. Gustafsson,et al.  Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. , 1999, The Journal of clinical investigation.

[25]  A. Jones,et al.  Clinical features and outcome of septic arthritis in a single UK Health District 1982–1991 , 1999, Annals of the rheumatic diseases.

[26]  A. Tarkowski,et al.  Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus , 1997, Infection and immunity.

[27]  J. Habbema,et al.  The outcome of bacterial arthritis: a prospective community-based study. , 1997, Arthritis and rheumatism.

[28]  T. Olsson,et al.  In situ hybridization analysis of synovial and systemic cytokine messenger RNA expression in superantigen-mediated Staphylococcus aureus arthritis. , 1996, Arthritis and rheumatism.

[29]  A. Tarkowski,et al.  The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model , 1993, Infection and immunity.

[30]  A. Tarkowski,et al.  Histopathological and serological progression of experimental Staphylococcus aureus arthritis , 1992, Infection and immunity.

[31]  A. Tarkowski,et al.  Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. , 1990, Arthritis and rheumatism.

[32]  L. Aarden,et al.  Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.

[33]  R. Bräuer,et al.  Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis , 2005, Inflammation Research.

[34]  S. Mochizuki,et al.  Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats , 2002, Journal of Bone and Mineral Metabolism.